Stelara 90 MG/ML syringeml
Ended Awarded
- Contract number
- SPE2DR26FCYU4
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $49,752
Award facts
- Contract value 100% obligated
- $49,752.39 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency has issued a delivery order valued at approximately $49,752 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Stelara 90 mg/ml syringes. This firm fixed-price delivery order, awarded on October 29, 2025, with an ultimate completion date of November 20, 2025, contains no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. The award falls under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy designed to provide comprehensive pharmaceutical support to Department of Defense healthcare operations globally.
DMS Pharmaceutical Group has established itself as a critical supplier within the federal pharmaceutical supply chain, with substantial contracting activity through the Defense Logistics Agency's Medical Supply Chain division. The company's product portfolio encompasses an extensive range of pharmaceuticals including branded and generic medications, biologics, vaccines, and medical consumables. The underlying PPV-G GEN V indefinite delivery contract, designated SPE2DR and awarded on November 13, 2025, carries a ceiling value of $499.999 billion and extends through December 31, 2036, with a 30-month base period followed by three optional 30-month periods, positioning DMS Pharmaceutical Group as a regional prime vendor contractor supporting military healthcare facilities worldwide.
Quick answers
Who was awarded contract SPE2DR26FCYU4?
SPE2DR26FCYU4 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on October 29, 2025.
How much is contract SPE2DR26FCYU4 worth?
The government has obligated $49,752 on SPE2DR26FCYU4.
Is contract SPE2DR26FCYU4 an order under another contract?
Yes. SPE2DR26FCYU4 is a delivery order under SPE2DR25D9127, an indefinite delivery contract.
Was contract SPE2DR26FCYU4 competed?
The extent of competition for SPE2DR26FCYU4 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award